De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Arix Bioscience Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	1.5yrs

Recente managementupdates

Recent updates

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Jan 13

CEO

Arix Bioscience heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Tom Davidson	COO & CFO	less than a year	geen gegevens	geen gegevens
Laura Craig	Investor Relations Officer	less than a year	geen gegevens	geen gegevens
Tassos Konstantinou	Managing Director	less than a year	geen gegevens	geen gegevens
Jade Fletcher	Financial Controller	1.1yrs	geen gegevens	geen gegevens
Felix Breyer	Associate	no data	geen gegevens	geen gegevens
Roy Bartel-Taverner	Analyst	no data	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van ARIX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peregrine David Euan Moncreiffe	Independent Non-Executive Chairman	2.8yrs	UK£150.00k	0.58% £ 1.0m
Andrew Smith	Independent Non-Executive Director	1.5yrs	UK£33.00k	geen gegevens
Debra Barker	Senior Independent Director	1.5yrs	UK£38.00k	0.040% £ 71.0k

1.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARIX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.

Arix Bioscience Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Arix Bioscience plc Announces Resignation of Directors

Independent Non-Executive Chairman recently bought UK£69k worth of stock

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Price target increased to UK£2.56

Less than half of directors are independent

Independent Non-Executive Chairman recently bought UK£78k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Price target increased to UK£2.56

Less than half of directors are independent

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Price target increased to UK£2.56

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

New 90-day high: UK£2.22

Executive Chairman recently bought UK£377k worth of stock

Investor sentiment improved over the past week

New 90-day high: UK£1.96

Market bids up stock over the past week

Analysts update estimates

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: UK£1.60

Price target raised to UK£1.71

New 90-day high: UK£1.12

New 90-day high - UK£0.97

Price target raised to UK£1.40

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

CEO

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd